Citations 14
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , DeCamp, Malcolm M., Dilling, Thomas J. , Dowell, Jonathan E. , Durm, Gregory A. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Grotz, Travis E. , Hegde, Aparna , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Patil, Tejas , Polanco, Patricio Marcelo , Tanvetyanon, Tawee , Yanagawa, Jane
Journal of the National Comprehensive Cancer Network | April 4, 2023 | Volume: 21 | Issue: 4 | Pages: 340-350
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options for eligible patients with resectable NSCLC.
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., DeCamp, Malcolm M., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Lackner, Rudy P., Maldonado, Fabien , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Pacheco, Jose M., Patel, Sandip Pravin , Riely, Gregory J. , Riess, Jonathan W. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Yau, Edwin , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Grotz, Travis E. , Hegde, Aparna , Lanuti, Michael D. , Lin, Jules , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Tanvetyanon, Tawee , Yanagawa, Jane
Journal of the National Comprehensive Cancer Network | May 11, 2022 | Volume: 20 | Issue: 5 | Pages: 497-530
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Hegde, Aparna , Hennon, Mark, Lackner, Rudy P., Leal, Ticiana , Lin, Jules , Martins, Renato , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Lanuti, Michael D. , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Yanagawa, Jane
Journal of the National Comprehensive Cancer Network | March 5, 2021 | Volume: 19 | Issue: 3 | Pages: 254-266
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., Dilling, Thomas J. , Dobelbower, M.C., Gettinger, Scott , Govindan, Ramaswamy , Gubens, Matthew A. , Hennon, Mark, Horn, Leora , Lackner, Rudy P., Leal, Ticiana , Lin, Jules , Loo, Billy W. , Martins, Renato , Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Shapiro, Theresa A. , Stevenson, James, Swanson, Scott J. , Tauer, Kurt W., Yang, Stephen C. , Gregory, Kristina M., OCN, Hughes, Miranda, Schild, Steven E. , Loo, Billy W , Govindan, Ramaswamy , Aggarwal, Charu , Bharat, Ankit , Chang, Joe Y. , Lanuti, Michael D. , Reckamp, Karen L. , OCN, Hughes, Miranda
Journal of the National Comprehensive Cancer Network | December 5, 2019 | Volume: 17 | Issue: 12 | Pages: 1464-1472
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as “preferred interventions,” whereas others are categorized as either “other recommended interventions” or “useful under certain circumstances.”